Thermo Fisher Scientific (NYSE:TMO) CEO Marc Casper Sells 275 Shares of Stock

Key Points

• CEO Marc Casper sold 275 Thermo Fisher shares at an average price of $627.05, generating $172,438.75. The transaction was made under a pre-arranged Rule 10b5-1 plan and reduced his direct ownership by 0.22%.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion, up 10.5% year over year. The company set fiscal 2026 EPS guidance at $24.93–$25.33.
• The stock recently traded at $634.48, near its 52-week high of $647, while analysts maintain a “Moderate Buy” consensus rating with an average target price of $619.41. The company also declared a quarterly dividend of $0.47 per share.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc Casper sold 275 shares of the business's stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $6.33 during trading hours on Wednesday, hitting $634.48. The stock had a trading volume of 1,842,596 shares, compared to its average volume of 2,274,136. The stock's fifty day simple moving average is $548.75 and its 200 day simple moving average is $510.05. The firm has a market capitalization of $234.60 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the firm posted $4.28 earnings per share. The business's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID boosted its stake in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Kilter Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $25,000. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $26,000. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 price target on the stock. Piper Sandler raised their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research note on Monday, July 27th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Finally, Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source